OncoMatch/Clinical Trials/NCT05555550
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Is NCT05555550 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 18F-Fluciclovine for glioma.
Treatment: 18F-Fluciclovine — The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE I, WHO GRADE II (WHO)
LGG including the brainstem and supratentorial only (WHO grade I-II)
Lab requirements
Kidney function
history of abnormal kidney function or creatinine ≥ CTCAE v5.0 grade 2 at time of study registration
Participants with a history of abnormal kidney function or creatinine ≥ CTCAE v5.0 grade 2 at time of study registration [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Children s Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify